Regulatory PathRegulatory requirements compared

Active substance

Lercanidipine

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Lertiv20 mgFilm-coated tablet · Oral use60 BlisterSAR 132.80Generic · PrescriptionSaudi AmaroxValid
Lertiv10 mgFilm-coated tablet · Oral use60 BlisterSAR 82.80Generic · PrescriptionSaudi AmaroxValid
Lertiv20 mgFilm-coated tablet · Oral use30 BlisterSAR 66.40Generic · PrescriptionSaudi AmaroxValid
Lertiv10 mgFilm-coated tablet · Oral use30 BlisterSAR 41.40Generic · PrescriptionSaudi AmaroxValid
LERCADIP 10MG F.C.TABLET10 mgFilm-coated tablet · Oral use30 BlisterSAR 44.35NCE · PrescriptionAlgorithm SALSuspended
LERCADIP 20 mg film-coated tablet20 mgFilm-coated tablet · Oral use30 BlisterSAR 71.15NCE · PrescriptionAlgorithm SALSuspended
Indications — CHI Daman Drug Formulary

CHRONIC KIDNEY DISEASE; HYPERTENSION

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
NHS Drug TariffLercanidipine 10mg tablets£1.4928 tablet1 Oct 2026
NHS Drug TariffLercanidipine 20mg tablets£2.3228 tablet1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.